The Relative Strength (RS) Rating for Lantheus Holdings climbed into a higher percentile Monday, as it got a lift from 69 to 75.
IBD's proprietary RS Rating identifies market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the trailing 52 weeks compares to the rest of the market.
History shows that the best stocks often have an RS Rating north of 80 in the early stages of their moves. See if Lantheus Holdings can continue to rebound and hit that benchmark.
Can You Really Time The Stock Market?
Lantheus Holdings is not currently near a potential buy zone. See if the stock goes on to build a base that could launch a new move.
Lantheus Holdings reported 16% EPS growth in its most recent report. Sales gains came in at 18%.
The company holds the No. 11 rank among its peers in the Medical-Products industry group. LeMaitre Vascular, Globus Medical and Penumbra are among the top 5 highly rated stocks within the group.
RELATED:
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
